NA
BSTC

Navellier & Associates’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Navellier & Associates’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,082
Closed -$861K – 325
2019
Q3 		$861K Sell
16,082
-227
-1% -$13.2K 0.14% 142
2019
Q2 		$974K Buy
16,309
+554
+4% +$34.9K 0.15% 136
2019
Q1 		$982K Buy
15,755
+11,055
+235% +$731K 0.15% 127
2018
Q4 		$285K Buy
+4,700
New +$281K 0.05% 186
2016
Q1 		– Sell
-11,488
Closed -$494K – 299
2015
Q4 		$494K Sell
11,488
-2,532
-18% -$127K 0.05% 124
2015
Q3 		$610K Buy
14,020
+4,414
+46% +$238K 0.06% 129
2015
Q2 		$496K Sell
9,606
-369
-4% -$15.7K 0.04% 203
2015
Q1 		$391K Sell
9,975
-2,407
-19% -$94.3K 0.04% 241
2014
Q4 		$478K Sell
12,382
-149
-1% -$5.68K 0.02% 202
2014
Q3 		$442K Buy
+12,531
New +$368K 0.02% 202

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Navellier & Associates's BSTC Position: Q4 2019 in Review

Navellier & Associates sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 16,082 shares — an estimated $861K sold.

Navellier & Associates first reported a position in BSTC in Q3 2014 and held it in 10 quarters. The position peaked at $982K in Q1 2019. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

  • Navellier & Associates reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
  • Navellier & Associates sold 16,082 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $861K.
  • Navellier & Associates first reported a position in BioSpecifics Technologies Corp. in Q3 2014 and held it in 10 quarters.
  • Navellier & Associates's BioSpecifics Technologies Corp. position peaked at $982K in Q1 2019.
  • 112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Navellier & Associates's 13F filing for Q4 2019, filed 12 Feb 2020.